A 10-year horizon under-states the case for acting in younger adults, and ESC says so plainly. But ESC applies the construct at every age and in both directions — the title reflects where it bites hardest, not where the guideline confines it.
(European Society of Cardiology, 2021)
The problem with the 10-year number under 50
“The 10-year CVD risk in relatively young, apparently healthy people is on average low, even in the presence of high risk factor levels, but the lifetime CVD risk is in these circumstances very high.”
“Women below 50 years and men below 40 years of age are almost invariably at low 10-year CVD risk, but may have unfavourable modifiable risk factors that sharply increase their longer-term CVD risk.”
“In risk communication with younger people, the lifetime benefit perspective may be useful, as well as discussing the potential of avoiding a devastating CVD event in the short-to-intermediate term, despite the fact that 10-year CVD risk may be very low.”
And the very next sentence, which bounds the whole frame:
“CVD risk predictions, as well as predictions of lifetime benefit of risk factor treatment, are likely to be imprecise at very young age (<40 years). At that age, lipid-lowering and BP-lowering drug treatment are not usually considered, except for patients with FH or specific BP disorders. A healthy lifestyle that is maintained throughout life is more relevant for the very young.”
(European Society of Cardiology, 2021)
So ESC bounds the very frame this page is about. The lifetime argument is not a licence to treat the young pharmacologically — below 40 the predictions themselves are called imprecise, and the guideline redirects to lifestyle. Any use of the three quotes above without this fourth sentence overstates the source, which is why it is reproduced here rather than cited.
The mechanism: risk-factor exposure compounds over decades while a 10-year window sees only the first slice. ESC states that «Age is the major driver of CVD risk», so a young person with a bad risk-factor profile still scores low over ten years. (inferred from European Society of Cardiology, 2021)
The route ESC provides — generic across every age band, not an under-50 exception
Not an under-50 special case. The same clause appears
verbatim in all three age sections, with only the threshold changing — <2.5% under 50, <5% at 50-69,
<7.5% at 70+. Lifetime benefit is a standing consideration at every age.
“A 10-year CVD risk <2.5% is considered ‘low-to-moderate risk’, and would generally not qualify for risk factor treatment unless one or several risk modifiers… increase risk, or the estimated lifetime risk and treatment benefit is considered substantial.”
And it runs bidirectionally — ESC uses the same construct to treat less in the old: “lifetime benefit of treatment in terms of time gained free of CVD is lower in older people. Therefore, the CVD risk thresholds for risk factor treatment are higher in apparently healthy people >=70 years.” (European Society of Cardiology, 2021)
Governing recommendation class: IIa, Level C — expert opinion, not trial evidence.
The unit — and it is a better unit than a percentage
ESC’s lifetime figures are expressed as:
“years of median life expectancy free from myocardial infarction or stroke”
Better than a 10-year event probability for a long-horizon decision, and directly communicable.
The endpoint includes death — it is not a pure CVD-free-time measure. Box 1: “Lifetime benefit is the numerical difference between the predicted age at which there is a 50% probability that a person will either have experienced a CVD event or have died with and without a proposed treatment.” So it is a composite of CVD event and all-cause death — which is why the grids fall so steeply with age, and why the tempting clean contrast CVD-free years, not years of life is false.
Box 1 also attaches the cost side: “the estimated individual lifetime benefit should be viewed in the light of the estimated duration of treatment. Duration of lifelong treatment will generally be longer in young persons compared to older people. Both treatment effect and treatment duration determine the individual ‘return on investment’.” A young person’s longer horizon is a longer treatment commitment, not only a larger gain.
(European Society of Cardiology, 2021)
How the numbers are built
“The lifetime benefit is calculated by estimating lifetime CVD risk with the LIFE-CVD model multiplied by the HR (0.78) from a meta-analysis of the effect of lipid lowering.”
“For 2 mmol/L LDL-C lowering, the average effect is almost twice as large, and so on.”
(European Society of Cardiology, 2021)
Read that construction carefully — it is the wiki’s own conversion move, done by the guideline. A lifetime baseline risk multiplied by a relative effect from a meta-analysis, expressed in absolute units. Exactly the pattern on Baseline Risk and the Relative-Absolute Split, with a lifetime rather than a 10-year baseline.
And note what that makes it: a MODELLED quantity, not a measured one. No trial followed anyone for a lifetime. The 0.78 is real trial evidence; the lifetime projection is a model. The dose-linearity claim (“almost twice as large” for 2 mmol/L) is likewise a property of the model.
The three grids ESC provides
| Figure | Intervention | Location |
|---|---|---|
| 11 | Smoking cessation | PDF p.49 |
| 12 | 1 mmol/L LDL-C reduction | PDF p.52 |
| 15 | 10 mmHg SBP reduction | PDF p.61 |
Figures 12 and 15 are by age x sex x smoking x SBP x non-HDL-C; Figure 11 has no smoking term — everyone in the smoking-cessation grid is a smoker by construction. All are live text in the PDF.
Two directions worth stating because they are counterintuitive: women gain more than men from the same LDL reduction (45-49 non-smoking: ~0.9-2.0 years vs ~0.6-1.6), and smokers gain less (men 45-49 smoking ~0.5-1.4). Competing risk is why.
Magnitudes, stated as a range rather than transcribed cell-by-cell. For a middle-aged man in the 45-49 band, 1 mmol/L of LDL-C lowering buys roughly 0.6 to 1.6 CVD-free years, rising with SBP and non-HDL and falling steeply with age — by 90+ the same intervention buys ~0.0-0.3 years.
Deliberately not transcribed cell-by-cell: the published figure misprints the 45-49 systolic labels
(they read 100-119 / 120-139 / 160-179 / 100-119), so row alignment cannot be established from the
render alone. A stated range is honest where a misaligned row would not be. A coordinate-clustered
extraction of all three grids is owed.
(European Society of Cardiology, 2021)
Decision relevance
- Under 50, ask for the lifetime number before accepting a low 10-year one. ESC’s own rule makes substantial lifetime benefit a qualifying route into treatment from the lowest band.
- CVD-free years gained is the more usable currency for a long-horizon decision than a 10-year percentage, and it is what ESC supplies.
- The benefit scales with the size of the reduction, but SUB-linearly. ESC says 2 mmol/L gives “almost twice as large” an effect — and “almost” is structural, since HR 0.78 compounds to 0.61 (a 1.78x ratio, not 2x). Reading this as “roughly linear” erases the direction of the shortfall — the benefit always falls short of proportional, never over.
- This does not settle treat or not. ESC is explicit that the lowest band “would generally not qualify for risk factor treatment”, and that under 40 drug treatment “is not usually considered”.
- Competing risk cuts the other way at older ages, which is why the grids fall so sharply: an intervention cannot buy CVD-free years to someone who will die of something else first.
(inferred from European Society of Cardiology, 2021)
Limits
- Calibrated for low- and moderate-risk regions only: “The model is currently validated for low- and moderate-risk countries.” It should not be read for high or very-high-risk regions.
- Modelled, not observed — see above. The wiki holds no validation of LIFE-CVD’s lifetime projections against realized outcomes, which is the standing R1 problem in its sharpest form: a lifetime projection is by construction unfalsifiable within a career.
- ESC notes there are no formal thresholds for AVERAGE lifetime benefit, and gives an instruction in their place: “the minimum desired benefit of a certain treatment needs to be established, a process in which patient preference, expected treatment harms, and costs can be taken into account.” It informs a decision by routing it to shared decision-making, not by leaving it open.
- One guidance body; whether others endorse lifetime framing or this model is unprobed.
The elderly-end companion - the diet levers transition with age, they do not flip at one (2026-08-01)
The “both directions” logic also answers a common question: at what age (say 45 to 70) do restrict-energy / lose-visceral-fat recommendations flip? There is no single flip age. Two continuous gradients govern it, not a birthday: the benefit of longevity plays declines with age (the lifetime-benefit gradient this page describes), shifting the outcome menu from mortality toward function; and energy restriction’s sarcopenia hazard rises as muscle reserve falls, so weight loss is reclassified from an unqualified lever to a conditional, muscle-protective one -> Protein and Resistance Training for Muscle and Strength, Does Weight Loss Reduce Cardiovascular Events. So the decision-relevant trigger is muscle status + remaining life expectancy + baseline risk, not chronological age - a sarcopenic 58-year-old is already on the preserve-muscle side; a robust, high-visceral-fat 68-year-old is not.
The cross-disease companion - the frame’s logic is not CVD-specific (2026-08-13)
The 10-year-horizon failure applies to every midlife-onset, long-latency modifiable lever, not just CVD. Dementia is the clearest case: in that body’s life-course table, midlife LDL, blood pressure, obesity, smoking and diabetes drive late-life incidence, so a low 10-year (single-disease) number understates them exactly as it does for CVD — and the same shared core pays into several late-life outcomes at once -> Shared Modifiable Levers Across Age-Related Diseases. What transports is the logic (act early despite a low short-horizon risk), not the apparatus: the LIFE-CVD model and the CVD-free-years currency above are CVD-specific, and the wiki holds no dementia/PD lifetime model. The below-40 “lifestyle over drugs” bound transports too; whether it goes further off-CVD is open, since the shared cardiometabolic-vascular substrate implies the CVD preventive drugs may themselves reduce dementia risk (unsettled). This extends the frame’s scope (wiki synthesis) - it is not a second guidance body endorsing lifetime framing (the unprobed gap in Limits stands).